๐ Heart attack patients face higher bleeding risk with new drug combo
Potent antiplatelet therapy increased bleeding risk without showing any benefit for cardiovascular events in patients with atrial fibrillation after a heart attack. This key finding came from the EPIDAURUS trial, conducted at 37 sites in Germany and Austria. The study compared a potent inhibitor combo versus a control group, which was prematurely stopped after 602 patients enrolled. The experimental group showed more than threefold higher rates of significant bleeding compared to the control group. Therefore, the results do not back the routine use of these potent P2Y12 inhibitors in this patient group. ๐